Abstract:Background Despite numerous clinical trials and decades of endeavour, there is still no effective cure for Alzheimer's disease. Computational drug repositioning approaches may be employed for the development of new treatment strategies for Alzheimer’s patients since an extensive amount of omics data has been generated during pre-clinical and clinical studies. However, targeting the most critical pathophysiological mechanisms and determining drugs with proper pharmacodynamics and good efficacy are equally crucial in drug repurposing and often imbalanced in Alzheimer’s studies. Methods Here, we investigated central co-expressed genes upregulated in Alzheimer’s disease to determine a proper therapeutic target. We backed our reasoning by checking the target gene’s estimated non-essentiality for survival in multiple human tissues. We screened transcriptome profiles of various human cell lines perturbed by drug induction (for 6798 compounds) and gene knockout using data available in the Connectivity Map database. Then, we applied a profile-based drug repositioning approach to discover drugs targeting the target gene based on the correlations between these transcriptome profiles. We evaluated the bioavailability, functional enrichment profiles and drug-protein interactions of these repurposed agents and evidenced their cellular viability and efficacy in glial cell culture by experimental assays and Western blotting. Finally, we evaluated their pharmacokinetics to anticipate to which degree their efficacy can be improved. Results We identified glutaminase as a promising drug target. Glutaminase overexpression may fuel the glutamate excitotoxicity in neurons, leading to mitochondrial dysfunction and other neurodegeneration hallmark processes. The computational drug repurposing revealed eight drugs: mitoxantrone, bortezomib, parbendazole, crizotinib, withaferin-a, SA-25547 and two unstudied compounds. We demonstrated that the proposed drugs could effectively suppress glutaminase and reduce glutamate production in the diseased brain through multiple neurodegeneration-associated mechanisms, including cytoskeleton and proteostasis. We also estimated the human blood–brain barrier permeability of parbendazole and SA-25547 using the SwissADME tool. Conclusions This study method effectively identified an Alzheimer’s disease marker and compounds targeting the marker and interconnected biological processes by use of multiple computational approaches. Our results highlight the importance of synaptic glutamate signalling in Alzheimer’s disease progression. We suggest repurposable drugs (like parbendazole) with well-evidenced activities that we linked to glutamate synthesis hereby and novel molecules (SA-25547) with estimated mechanisms for the treatment of Alzheimer’s patients.

In silico drug repurposing by combining machine learning classification model and molecular dynamics to identify a potential OGT inhibitor

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

Drug repurposing against galectin-3 using simulation-based studies

A Machine Learning Algorithm Suggests Repurposing Opportunities for Targeting Selected GPCRs

A Genome-Wide Positioning Systems Network Algorithm for in Silico Drug Repurposing

Virtual Screening of Human O-Glcnac Transferase Inhibitors

Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients

Drug Repositioning Targeting Glutaminase Reveals Drug Candidates for the Treatment of Alzheimer’s Disease Patients

Metabolic modeling-based drug repurposing in Glioblastoma

Machine-Learning Driven Drug Repurposing for COVID-19

In Silico Drug Repositioning for the Treatment of Alzheimer's Disease Using Molecular Docking and Gene Expression Data

Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties

Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding

Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features

Recent advances in drug repurposing using machine learning

Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing

A COVID-19 Drug Repurposing Strategy Through Quantitative Homological Similarities by using a Topological Data Analysis Based Formalism

Integrated Molecular Modeling and Machine Learning for Drug Design

Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach.

Machine learning driven web-based app platform for the discovery of monoamine oxidase B inhibitors